NI202100021A - Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina - Google Patents

Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina

Info

Publication number
NI202100021A
NI202100021A NI202100021A NI202100021A NI202100021A NI 202100021 A NI202100021 A NI 202100021A NI 202100021 A NI202100021 A NI 202100021A NI 202100021 A NI202100021 A NI 202100021A NI 202100021 A NI202100021 A NI 202100021A
Authority
NI
Nicaragua
Prior art keywords
modified
preparation
dosage form
oral dosage
procedure
Prior art date
Application number
NI202100021A
Other languages
English (en)
Inventor
Saura I Valls Marc
Nebot Troyano Joaquín
M Roca I Juanes Ramon
Original Assignee
Inibsa Ginecologia S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inibsa Ginecologia S A filed Critical Inibsa Ginecologia S A
Publication of NI202100021A publication Critical patent/NI202100021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada que comprende una pluralidad de pellets de liberación modificada de doxilamina o una sal de la misma y una pluralidad de pellets de liberación modificada de piridoxina o una sal de la misma, en el que el procedimiento comprende recubrir los pellets de doxilamina que tienen la capa de recubrimiento activa interna y la capa de recubrimiento entérico intermedia y los pellets de piridoxina que tienen la capa de recubrimiento activa interna, en el que la etapa de recubrimiento comprende la pulverización simultánea de una mezcla que comprende los agentes de recubrimiento de liberación entérica y modificada y la adición de agentes formadores de poros en forma de polvo.
NI202100021A 2018-09-27 2021-03-23 Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina NI202100021A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382687.4A EP3628311B1 (en) 2018-09-27 2018-09-27 A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride

Publications (1)

Publication Number Publication Date
NI202100021A true NI202100021A (es) 2021-06-30

Family

ID=63722327

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202100021A NI202100021A (es) 2018-09-27 2021-03-23 Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina

Country Status (31)

Country Link
EP (1) EP3628311B1 (es)
JP (1) JP7444862B2 (es)
KR (1) KR20210066864A (es)
CN (1) CN112839638B (es)
AR (1) AR116480A1 (es)
AU (1) AU2019348630B2 (es)
BR (1) BR112021005192A8 (es)
CL (1) CL2021000687A1 (es)
CO (1) CO2021005412A2 (es)
CR (1) CR20210208A (es)
CY (1) CY1123785T1 (es)
DK (1) DK3628311T3 (es)
DO (1) DOP2021000052A (es)
EA (1) EA202190700A1 (es)
EC (1) ECSP21029863A (es)
ES (1) ES2847648T3 (es)
HR (1) HRP20210181T1 (es)
HU (1) HUE053082T2 (es)
MX (1) MX2021003357A (es)
MY (1) MY197676A (es)
NI (1) NI202100021A (es)
PE (1) PE20211462A1 (es)
PH (1) PH12021550640A1 (es)
PL (1) PL3628311T3 (es)
PT (1) PT3628311T (es)
RS (1) RS61368B1 (es)
SA (1) SA521421557B1 (es)
SI (1) SI3628311T1 (es)
UA (1) UA127768C2 (es)
WO (1) WO2020064985A1 (es)
ZA (1) ZA202101279B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
CN101448493A (zh) * 2006-05-22 2009-06-03 特瓦制药工业有限公司 度洛西汀盐酸盐延迟释放配制剂
ES2376095B1 (es) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. Pellets entéricos de duloxetina.
CA2761212A1 (en) * 2011-12-07 2013-06-07 Pharmascience Inc. Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
SG11201403931YA (en) * 2012-02-22 2014-08-28 Duchesnay Inc Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
CN103690506B (zh) * 2013-11-08 2015-05-13 舒泰神（北京）生物制药股份有限公司 一种曲司氯铵缓释组合物及其制备方法
SG11201701448XA (en) * 2014-08-29 2017-03-30 Duchesnay Inc Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
JP6695337B2 (ja) * 2014-11-26 2020-05-20 レーム・ゲーエムベーハーＲｏｅｈｍ ＧｍｂＨ エタノールの影響に対する耐性を有する医薬品組成物または栄養機能食品組成物
CN106606502B (zh) * 2015-10-27 2019-12-31 四川海思科制药有限公司 一种琥珀酸多西拉敏盐酸吡哆醇肠溶片药物组合物及其制备方法

Also Published As

Publication number Publication date
UA127768C2 (uk) 2023-12-27
CY1123785T1 (el) 2022-05-27
PT3628311T (pt) 2021-02-09
MX2021003357A (es) 2021-08-11
RS61368B1 (sr) 2021-02-26
EP3628311A1 (en) 2020-04-01
ZA202101279B (en) 2021-10-27
JP2022502406A (ja) 2022-01-11
EA202190700A1 (ru) 2021-07-01
PE20211462A1 (es) 2021-08-05
AU2019348630B2 (en) 2024-07-11
WO2020064985A1 (en) 2020-04-02
JP7444862B2 (ja) 2024-03-06
ES2847648T3 (es) 2021-08-03
EP3628311B1 (en) 2020-11-11
MY197676A (en) 2023-07-03
AR116480A1 (es) 2021-05-12
DK3628311T3 (da) 2021-02-01
CL2021000687A1 (es) 2021-08-06
PL3628311T3 (pl) 2021-07-05
SI3628311T1 (sl) 2021-04-30
ECSP21029863A (es) 2021-05-31
BR112021005192A2 (pt) 2021-06-08
PH12021550640A1 (en) 2022-02-14
CR20210208A (es) 2021-06-23
CN112839638B (zh) 2023-12-19
DOP2021000052A (es) 2021-06-30
HRP20210181T1 (hr) 2021-03-19
HUE053082T2 (hu) 2021-06-28
BR112021005192A8 (pt) 2023-04-11
CO2021005412A2 (es) 2021-05-10
AU2019348630A1 (en) 2021-05-13
SA521421557B1 (ar) 2022-10-30
CN112839638A (zh) 2021-05-25
KR20210066864A (ko) 2021-06-07

Similar Documents

Publication Publication Date Title
ES2631980T3 (es) Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables
CL2015001891A1 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014).
CL2016000117A1 (es) Autotaxina inhibidores comprende un anillo heteroaromático-bencilamina ciclo basico
CL2014000131A1 (es) Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada que comprende pirfenidona; y su uso para el tratamiento o regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica.
EA201201508A1 (ru) Комбинированная терапия
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
MX2010009731A (es) Composiciones farmaceuticas de una combinacion de metformina y un inhibidor de dipeptidil peptidasa-iv.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
AR098417A1 (es) Formulación farmacéutica combinada que comprende amlodipina, losartán y rosuvastatina
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion
NI202100021A (es) Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CR20190145A (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
MX2021003033A (es) Formulaciones de compuestos de cicloserina y aplicaciones de estas.
GT201300032A (es) Composicion farmaceutica de liberacion prolongada de trimetazidina
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
UY38028A (es) Combinación farmacéutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y su uso para el tratamiento del dolor
CR20220527A (es) Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
EP3813801A4 (en) OSMOTIC EXTENDED RELEASE TABLET DOSAGE FORM WITH METFORMIN AND SITAGLIPTIN
AR124515A2 (es) 2-(1-(9h-purin-6-ilamino)propil)-3-(3-fluorofenil)-4h-cromen-4-ona y (s)-2-(1-(9h-purin-6-ilamino)propil)-3-(3-fluorofenil)-4h-cromen-4-ona, composición farmacéutica; métodos relacionados, y uso de dichos compuestos para fabricar medicamentos
AR109253A1 (es) Composición de teneligliptina y metformina y proceso para prepararla
ECSP16086746A (es) Formulación inmunosupresora